Once-Monthly MariTide Shows Promising Weight Loss in Obesity and Type 2 Diabetes: Phase 2 Trial
USA: A once-monthly injectable therapy, maridebart cafraglutide (MariTide), demonstrated significant weight loss in individuals with obesity-with and without type 2 diabetes-according to a new phase 2 clinical trial published in The New England Journal of Medicine. The trial, led by Dr. Ania M. Jastreboff from Yale School of Medicine and her colleagues, explored the efficacy and safety of this novel dual-action peptide–antibody conjugate over 52 weeks.
MariTide is designed to combine the effects of glucagon-like peptide-1 (GLP-1) receptor activation with glucose-dependent insulinotropic polypeptide (GIP) receptor antagonism. This unique mechanism targets key metabolic pathways involved in appetite regulation, insulin sensitivity, and weight management.
The study enrolled a total of 592 adults, divided into two cohorts: individuals with obesity (465 participants) and those with both obesity and type 2 diabetes (127 participants). Participants were randomized to receive various dosing regimens of maridebart cafraglutide or a placebo injection over a year. Doses ranged from 140 mg to 420 mg, administered every four or eight weeks, with some groups undergoing dose escalation to evaluate tolerability.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.